Research programme: calcium channel antagonists - VM DiscoveryAlternative Names: VMD-C300 series
Latest Information Update: 19 Jan 2011
At a glance
- Originator VM Discovery
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Epilepsy; Hypertension; Pain
Most Recent Events
- 21 Feb 2007 Preclinical trials in Pain in USA (unspecified route)
- 21 Feb 2007 Preclinical trials in Hypertension in USA (unspecified route)
- 21 Feb 2007 Preclinical trials in Cardiovascular disorders in USA (unspecified route)